Shanghai Ruizhou Biotechnology
Advanced pneumococcal conjugate vaccines for broader pathogenic coverage
About Shanghai Ruizhou Biotechnology
Shanghai Ruizhou Biotechnology Co., Ltd. is a biopharmaceutical company established in September 2017 by Dr. Xianchao Zhu, a returning expert from the US. The company focuses on the research, development, and industrialization of innovative vaccines and recombinant protein biologies. Dr. Zhu, a University of California biology PhD, has over two decades of experience in new drug and vaccine development at leading global pharmaceutical companies like Pfizer and later served as a department head at the US Pharmacopoeia's R&D center in China. His extensive background includes leading over 25 new drug development projects, with three achieving FDA market approval.
The company's core product is a self-developed 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24). This vaccine was created to address the specific pathogenic strains prevalent in China and aims to increase protection coverage from the current 75% to over 90%. It utilizes a novel non-toxic dual-protein carrier technology. Ruizhou Bio has received clinical approval for the vaccine across all age groups. As of June 2025, the clinical research for adults has completed Phase II trials, with Phase III set to begin, while the Phase I trial for infants and young children has yielded initial data.
Ruizhou Biotechnology has secured significant funding, including a strategic investment in 2017 from Changchun High-Tech Group, which, along with its subsidiary BCHT Biotechnology, has invested a total of 316 million RMB for a 50% stake. More recently, the company completed a Series A+ financing round of tens of millions of RMB in June 2025, led by Changxing Fund. To manage its entire value chain, Ruizhou established Shanghai Weizhou Biotechnology in March 2021, a GMP-level pilot R&D and production workshop in Shanghai. Furthermore, it founded Changchun Ruizhou Biopharmaceutical Co., Ltd. in May 2020 to construct a large-scale, international-standard GMP production base in Changchun, with a potential annual capacity of over 100 million vaccine doses.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jan 2026 | $28M | $110M | Undisclosed | ↗ |
| SERIES A✓Equity / VC | Jun 2025 | $2.8M | $11M | Changxing Fund | ↗ |
Growth signals
Shanghai Ruizhou Biotechnology's team grew 20% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
ARCALISContract development and manufacturing organization ("CDMO") for mRNA vaccines and therapeutics |
Nomi, Japan | Operational | 31 | $224M | $272M |
| China | Operational | ||||
Kangle Guardian BiologicalInnovative human papillomavirus (HPV) vaccine development company |
China | Operational | |||
Taiwan Universe BioMedicineDeveloping bivalent enterovirus and influenza VLP vaccines. [2, 4, 6, 8] |
Taiwan | Operational | |||
| Pudong, China | Operational | ||||
| China | Operational | ||||
ElisigenAAV gene therapies for neurodegenerative and rare diseases |
Seoul, South Korea | Operational | |||
CHA Vaccine InstituteTea vaccine research is a state-of-the-art biotech company developing vaccines and immunotherapys |
South Korea | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Ruizhou Biotechnology in its local ecosystem
The Shanghai Ruizhou Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Changxing Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Ruizhou Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Ruizhou Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






